Form 4: Collegium Pharmaceutical EVP & General Counsel Receives Stock Grant

David Dieter, EVP & General Counsel of Collegium Pharmaceutical, received a grant of 68,449 restricted stock units (RSUs) on March 17, 2025.

Summary

• David Dieter, the EVP & General Counsel of Collegium Pharmaceutical, received 68,449 restricted stock units (RSUs) on March 17, 2025.
• Each RSU represents a contingent right to receive one share of Collegium Pharmaceutical's common stock.
• 33% of the RSUs will vest on March 17, 2026, with the remaining balance vesting in two annual installments thereafter, contingent upon Dieter's continued service with the company.
• The RSUs will be settled in shares of Collegium Pharmaceutical's common stock on each applicable vesting date.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of executive compensation, which is generally viewed neutrally. The vesting schedule suggests a long-term commitment from the executive, which is a positive signal.

Positives

• The grant of RSUs aligns the executive's interests with those of the shareholders, incentivizing continued service and performance.

Risks

• The value of the RSUs is dependent on the future stock price of Collegium Pharmaceutical, which is subject to market fluctuations and company performance.

Future Outlook

The vesting schedule of the RSUs extends over three years, indicating a long-term incentive for the executive.

Industry Context

Stock grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive incentive for the executive to drive company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

restricted stock units, RSUs, stock grant, executive compensation, Form 4, Collegium Pharmaceutical, David Dieter